VORANIGO (vorasidenib) is an IDH1/IDH2 inhibitor approved by the FDA on 6 August 2024 for adult and pediatric patients 12 years and older with surgically intervened Grade 2 astrocytoma/oligodendroglioma harboring IDH1/IDH2 mutations [23]. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).